Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_151_библиотеки_им_акад_М_И_Перельмана
.pdf
The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy 399
https://t.me/med1917
Lohneis P, Sinn M, Bischoff S, Juhling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C,
Oettle H, Blaker H, Riess H, Johrens K, Striefler JK (2017) Cytotoxic tumour-infiltrating T
lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:
290–301. https://doi.org/10.1016/j.ejca.2017.06.016
Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3(6):
459–465. https://doi.org/10.1038/nrc1097
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman
JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P,
Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A,
Simon JS, Xu L-A, Waxman IM, Sharma P, Investigators C (2015) Nivolumab versus
Everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.
org/10.1056/NEJMoa1510665
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER,
Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK,
Salman P, Gurney H, Hawkins R, Ravaud A, Grimm M-O, Bracarda S, Barrios CH, Tomita Y,
Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P,
Hammers HJ, Escudier B (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced
renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/
NEJMoa1712126
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B,
Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH, Gurney H,
Schmidinger M, Larkin J, Atkins MB, Bedke J, Alekseev B, Wang J, Mariani M, Robbins
PB, Chudnovsky A, Fowst C, Hariharan S, Huang B, di Pietro A, Choueiri TK (2019)
Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med
380(12):1103–1115. https://doi.org/10.1056/NEJMoa1816047
Mucileanu A, Chira R, Mircea PA (2021) PD-1/PD-L1 expression in pancreatic cancer and its
implication in novel therapies. Med Pharm Rep 94(4):402–410. https://doi.org/10.15386/
MPR-2116
Nasrollahzadeh E, Razi S, Keshavarz-Fathi M, Mazzone M, Rezaei N (2020) Pro-tumorigenic
functions of macrophages at the primary, invasive and metastatic tumor site. Cancer Immunol
Immunother 69(9):1673–1697. https://doi.org/10.1007/s00262-020-02616-6
Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M, Boudreau JE
(2021) NK cell infiltration is associated with improved overall survival in solid cancers: a
systematic review and meta-analysis. Transl Oncol 14(1):100930. https://doi.org/10.1016/J.
TRANON.2020.100930
Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H,
Azuma M, Nakajima Y (2007) Clinical significance and therapeutic potential of the
programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin
Cancer Res 13(7):2151–2157. https://doi.org/10.1158/1078-0432.CCR-06-2746
Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, Gögenur I (2020)
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic
review and meta-analysis. Eur J Cancer 132:71–84. https://doi.org/10.1016/j.ejca.2020.03.013
Oshima M, Okano K, Muraki S, Haba R, Maeba T, Suzuki Y, Yachida S (2013)
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and
SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann
Surg 258(2):336–346. https://doi.org/10.1097/SLA.0B013E3182827A65
Ott PA, Bang Y-J, Piha-Paul SA, Abdul AR, Razak JB, Soria J-C, Rugo HS, Cohen RB, O’Neil
BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K,
Stein K, Ayers M, Joe AK, Lunceford JK (2019a) T-cell-inflamed gene-expression profile,
programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients
treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318–327.
https://doi.org/10.1200/JCO.2018.78.2276
400 A. Orhan
https://t.me/med1917
Ott PA, Bang Y-J, Piha-Paul SA, Razak ARA, Bennouna J, Soria J-C, Rugo HS, Cohen RB, O’Neil
BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K,
Stein K, Ayers M, Joe AK, Lunceford JK (2019b) T-cell-inflamed gene-expression profile,
programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients
treated with Pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37(4):318–327.
https://doi.org/10.1200/JCO.2018.78.2276
Ottenhof NA, Morsink FHM, ten Kate F, van Noorden CJF, Offerhaus GJA (2012) Multivariate
analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adeno-
carcinoma reveals prognostic significance for persistent Smad4 expression only. Cell Oncol
35(2):119–126. https://doi.org/10.1007/S13402-012-0072-X/TABLES/4
Padua D, Massagué J (2008) Roles of TGFβ in metastasis. Cell Res 19(1):89–102. https://doi.org/
10.1038/cr.2008.316
Paijens ST, Vledder A, de Bruyn M, Nijman HW (2020) Tumor-infiltrating lymphocytes in the
immunotherapy era. Cell Mol Immunol 18(4):842– 859. https://doi.org/10.1038/s41423-020-
00565-9
Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R,
Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Nicole Li X, Pierce RH,
Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW (2015) Phase I study of
Pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid
tumors. Clin Cancer Res 21(19):4286–4293. https://doi.org/10.1158/1078-0432.CCR-14-2607
Porembka MR, Mitchem JB, Belt BA, Hsieh CS, Lee HM, Herndon J, Gillanders WE, Linehan DC,
Goedegebuure P (2012) Pancreatic adenocarcinoma induces bone marrow mobilization of
myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol
Immunother 61(9):1373–1385. https://doi.org/10.1007/S00262-011-1178-0/FIGURES/7
Pu N, Lou W, Yu J (2019) PD-1 immunotherapy in pancreatic cancer: current status. Journal
Pancreatol 2(1):6–10. https://doi.org/10.1097/JP9.0000000000000010
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting
cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas
cancers in the United States. Cancer Res 74(11):2913–2921. https://doi.org/10.1158/0008-5472.
CAN-14-0155
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D,
Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D,
Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang Y-H, Tamada S, Shou Q,
Perini RF, Chen M, Atkins MB, Powles T (2019) Pembrolizumab plus Axitinib versus Sunitinib
for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127. https://doi.org/10.1056/
NEJMoa1816714
Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O (2018) Trends in pancreatic adenocarcinoma
incidence and mortality in the United States in the last four decades; a SEER-based study. BMC
Cancer 18(1):688. https://doi.org/10.1186/s12885-018-4610-4
Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, García-Milian R,
Mehta S, Reshetnyak YK, Bahal R, Fiorina P, Glazer PM, Rimm DL, Fernández-Hernando C,
Suárez Y (2019) Suppressing miR-21 activity in tumor-associated macrophages promotes an
antitumor immune response. J Clin Invest 129(12):5518–5536. https://doi.org/10.1172/
JCI127125
Santos MF, Mannam VKR, Craft BS, Puneky LV, Sheehan NT, Lewis RE, Cruse JM (2014)
Comparative analysis of innate immune system function in metastatic breast, colorectal, and
prostate cancer patients with circulating tumor cells. Exp Mol Pathol 96(3):367–374. https://doi.
org/10.1016/j.yexmp.2014.04.001
Shi H, Li J, Fu D (2016) Process of hepatic metastasis from pancreatic cancer: biology with clinical
significance. J Cancer Res Clin Oncol 142(6):1137–
2024-0
1161. https://doi.org/10.1007/s00432-015-
The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy 401
https://t.me/med1917
Stylianou A, Gkretsi V, Stylianopoulos T (2018) Transforming growth factor-β modulates pancre-
atic cancer associated fibroblasts cell shape, stiffness and invasion. Biochim Biophys Acta Gen
Subj 1862(7):1537–1546. https://doi.org/10.1016/J.BBAGEN.2018.02.009
Takeuchi Y, Nishikawa H (2016) Roles of regulatory T cells in cancer immunity. Int Immunol
28(8):401–409. https://doi.org/10.1093/intimm/dxw025
Tascilar M, Offerhaus GJA, Altink R, Argani P, Sohn TA, Yeo CJ, Cameron JL, Goggins M,
Hruban RH, Wilentz RE (2001) Immunohistochemical labeling for the Dpc4 gene product is a
specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J
Clin Pathol 116(6):831–837. https://doi.org/10.1309/WF03-NFCE-7BRH-7C26
Tykodi SS (2014) PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
Onco Targets Ther 7:1349–1359. https://doi.org/10.2147/OTT.S48443
van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM (2017) Migrating into the
tumor: a roadmap for T cells. Trends Cancer 3(11):797–808. https://doi.org/10.1016/j.trecan.
2017.09.006
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W,
Li G, Zeng Z, Guo C (2017) Role of tumor microenvironment in tumorigenesis. J Cancer 8(5):
761–773. https://doi.org/10.7150/jca.17648
Wang F, Lau JKC, Yu J (2020a) The role of natural killer cell in gastrointestinal cancer: killer or
helper. Oncogene 40(4):717–730. https://doi.org/10.1038/s41388-020-01561-z
Wang X, Li X, Wei X, Jiang H, Lan C, Yang S, Wang H, Yang Y, Tian C, Xu Z, Zhang J, Hao J,
Ren H (2020b) PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma
(PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in
the treatment of PDAC. Signal Transduct Target Ther 5(1):1–12. https://doi.org/10.1038/
s41392-020-0144-8
Waters AM, Der CJ (2018) KRAS: the critical driver and therapeutic target for pancreatic cancer.
Cold Spring Harb Perspect Med 8(9):a031435. https://doi.org/10.1101/CSHPERSPECT.
A031435
Whatcott CJ, Posner RG, von Hoff DD, Han H (2012) Desmoplasia and chemoresistance in
pancreatic cancer. In: Grippo PJ, Munshi HG (eds) Pancreatic cancer and tumor microenviron-
ment. Transworld Research Network, Trivandrum
Wu W, Liu Y, Zeng S, Han Y, Shen H (2021) Intratumor heterogeneity: the hidden barrier to
immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-
infiltrating lymphocytes. J Hematol Oncol 14(1):1–28. https://doi.org/10.1186/S13045-021-
01166-3
Xing S, Yang H, Liu J, Zheng X, Feng J, Li X, Li W (2016) Prognostic value of SMAD4 in
pancreatic cancer: a meta-analysis. Transl Oncol 9(1):1. https://doi.org/10.1016/J.TRANON.
2015.11.007
Yang S, Liu Q, Liao Q (2021) Tumor-associated macrophages in pancreatic ductal adenocarci-
noma: origin, polarization, function, and reprogramming. Front Cell Dev Biol 8:1552. https://
doi.org/10.3389/FCELL.2020.607209/BIBTEX
Zhang J, Wang YF, Wu B, Zhong ZX, Wang KX, Yang LQ, Wang YQ, Li YQ, Gao J, Li ZS (2017)
Intraepithelial attack rather than Intratumorally infiltration of CD8+T lymphocytes is a favorable
prognostic indicator in pancreatic ductal adenocarcinoma. Curr Mol Med 17(10):689–698.
https://doi.org/10.2174/1566524018666180308115705
Zhao J, Liang Y, Yin Q, Liu S, Wang Q, Tang Y, Cao C (2016) Clinical and prognostic significance
of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarci-
noma. Braz J Med Biol Res 49:8. https://doi.org/10.1590/1414-431X20165485
Zheng L (2017) PD-L1 expression in pancreatic cancer. JNCI: J Natl Cancer Inst 109:6. https://doi.
org/10.1093/JNCI/DJW304
Zheng X, Song X, Shao Y, Xu B, Hu W, Zhou Q, Chen L, Zhang D, Wu C, Jiang J (2018)
Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell
Physiol Biochem 45(2):720–732.
https://doi.org/10.1159/000487164
Index
https://t.me/med1917
A
Angiogenesis, 18, 24, 30, 31, 50, 51, 55, 126,
153, 156, 159, 160, 162, 164, 166, 167,
170–172, 196, 216, 221– 224, 270, 333,
336, 361, 383, 388, 391, 392
B
Biomaterial, 275, 279–280
C
Cancer immunotherapy, 3, 10, 219, 226, 297–
298, 348
CAR NK cell therapy, 347–348, 363
Carcinogenesis, 8, 29, 53, 58, 73, 102, 119,
126, 133, 137, 138, 140, 141, 154, 165–
167, 169, 235–241, 245, 257, 282, 330,
333, 338, 392
Checkpoint inhibitors, 3, 34, 60, 105, 109, 194,
203, 204, 219, 220, 252, 253, 255–256,
298, 348, 350, 382, 386
Chemotherapy (CT), 9, 11, 12, 34, 36, 58, 81,
109, 112, 143, 199, 203, 217, 222, 242–
244, 252, 256, 270, 292, 293, 295–298,
307–310, 330, 333, 340, 348, 352, 357,
361, 363, 389
Chimeric antigen receptor (CAR) T-cell
therapy, 9, 10, 13, 251–262, 330, 331,
340, 342–347, 363
Cholangiocarcinoma, 7, 12, 60–61, 361
Colon cancer, 4, 5, 88, 115, 156, 158, 164, 167,
168, 170–172, 187–204, 233–245, 264,
280–282, 357
Colorectal cancer (CRC), 2, 12, 25, 54–57, 70,
83–85, 88, 89, 111, 151–172, 188, 189,
191, 192, 194, 197, 199, 203, 239, 243,
254, 256, 257, 269–283, 291–298
Cytotoxic T lymphocyte-associated protein
4 (CTLA-4), 3, 4, 8, 9, 13, 34, 107, 199,
200, 203, 219, 220, 222, 244, 255, 261,
348–352
Cytotoxin-associated gene A (CagA), 53, 102,
119, 121, 122, 124–126, 140, 141
D
Dysbiosis, 2, 17, 19, 25–27, 29, 32, 33, 138,
143, 235, 237, 239–243
E
Early-onset colorectal cancer, 291–298
Epidemiology, 4–5, 102–104, 319, 382
Esophageal cancer (EC), 3, 18, 25, 51, 52, 62,
70, 71, 84, 89–91, 135, 215–228, 254,
256, 259, 305–320
Esophagectomy, 3, 307–320
G
Gastric cancer (GC), 2–4, 7, 9, 11, 26, 32, 52,
70, 72, 86–89, 101–112, 117–126,
133–144, 151–172, 252, 254, 258
Gastric carcinoma, 102, 118, 134, 135, 138, 347
Gastrointestinal cancer, 1–13, 17–36, 45–62,
69–91, 251–262, 343
Gut microbiota, 22–29, 35, 73, 142, 233–245,
311–314
H
Helicobacter pylori (H. pylori), 4, 5, 7, 14, 25,
26, 32, 53, 102, 103, 117–144, 164
Helicobacter pylori infection, 4, 5, 7, 26, 32,
118, 126, 134–137, 139–144
#
The Editor(s) (if applicable) and The Author(s), under exclusive license to
Springer Nature Switzerland AG 2023
Interdisciplinary Cancer Research 4, https://doi.org/10.1007/978-3-031-48371-4
403
404 Index
https://t.me/med1917
Hepatocellular carcinoma (HCC), 5, 26, 33,
59–60, 71, 86, 258
I
Immune checkpoint blockade (ICB), 8, 35, 36,
330, 332, 348–353, 356
Immune nutrition (IN), 101–112
Immune response, 3, 9, 10, 19, 24–26,
29–35, 49, 72, 106, 107, 109–111,
120, 121, 164, 189, 193, 194, 203,
204, 220, 222, 223, 225, 244, 253,
256, 271, 330–332, 334, 338, 339,
346, 357, 360, 386, 388–390
Immune system, 2, 8, 9, 13, 19, 23–25, 27, 28,
31–33, 72, 87, 101–112, 196, 218–224,
234, 235, 237, 244, 253–255, 260,
261, 298, 334, 336, 340, 347, 353,
382–387, 390
Immunity, 2, 9, 10, 17–36, 107, 111, 193, 218,
221–223, 233–245, 254, 337, 338, 346,
352, 360, 383, 391
Immunoediting, 2, 200
Immunohistochemistry (IHC), 111, 194
Immunotherapy, 3, 6, 8–13, 33, 106, 109,
204, 216, 219, 221, 222, 224–226,
244–245, 251–262, 271, 297–298,
330, 339, 341, 348, 353, 354, 360,
363, 381–395
Inflammatory response, 28, 126, 140, 203, 238,
239, 258, 294, 315
Innate immune cells, 34, 254
L
Liver cancer (LC), 5, 11, 18, 33, 61, 70, 71,
85–86, 259
M
MALT lymphoma, 134, 143
Mass spectrometry (MS), 73, 75–77, 85
Melatonin, 61–62
Mesenchymal to epithelial transition, 45–62,
171, 195, 200, 393
Metabolomics, 52, 59, 69–91
Microbiome, 18, 25, 26, 138, 234–237,
239, 241
Microbiota, 17
Migrastatics, 61, 62
–36, 142, 173, 233–245,
311, 314
N
Nanocarrier, 269–283
Nanomedicine, 272, 282, 283
Neo-angiogenesis, 49, 382, 383, 392, 393
Neuroendocrine, 57, 59, 159, 221
Neuropeptides, 153, 165–168
Neurotransmitters, 153–154, 156, 168, 169
Nuclear magnetic resonance spectroscopy
(NMR), 73, 75, 77–79
O
Oncolytic virus therapy (OVT), 331, 332,
339–340
P
Pancreas, 2, 4, 5, 18, 26, 27, 33, 58, 82, 164,
252, 332, 338, 343, 347
Pancreatic cancer (PC), 7, 12, 26, 27, 33, 57–59,
70, 73, 80, 81, 259, 327–363, 381–395
Pancreatic ductal adenocarcinoma (PDAC),
57–59, 257, 330, 383, 389, 392
Pogrammed death 1 (PD-1), 3, 8, 9, 11, 13, 34,
35, 61, 105, 109, 112, 194, 203,
218–220, 224, 225, 244, 255, 261, 298,
331, 333, 339, 341, 348–353, 360, 361,
363, 390
Prognostic prediction, 217
R
Radiotherapy, 3, 11, 12, 34, 105, 199, 252,
292–298, 308, 309, 333, 360
T
Treatment, 3, 19, 60, 71, 105, 135, 153, 188,
216, 234, 252, 270, 292, 306, 330, 382
Tumor-infiltrating lymphocytes (TIL), 10, 337,
382, 386
V
Vacuolating toxin (VacA), 102, 119, 122–126,
140, 141
Virulence factors, 117–144, 238
W
Weight loss, 70, 87, 110, 143, 252, 305–320
Wingless and INT-1 (Wnt), 49, 50, 52–56, 59,
125, 164, 238, 346
Соседние файлы в папке Библиотека им академика М.И. Перельмана